CombiGene

CombiGene AB is a Swedish biopharmaceutical company focused on developing gene therapies for neurological diseases, particularly epilepsy. The company’s lead product, CG01, is a gene therapy currently in the preclinical phase, utilizing an adeno-associated viral vector to deliver a combination of neuropeptide Y and its receptor directly to the brain regions associated with seizure activity. This innovative approach aims to provide effective treatment options for epilepsy patients who currently lack adequate medical solutions. CombiGene has also established collaborations, including a licensing agreement with Lipigon Pharmaceuticals for developing therapies for lipodystrophy and a partnership with Cobra Biologics for advancing CG01. Founded in 1999 and headquartered in Lund, Sweden, CombiGene is dedicated to improving the quality of life for patients suffering from severe, life-altering conditions through its groundbreaking gene therapy initiatives.